176 related articles for article (PubMed ID: 26775675)
1. Targeting translation: eIF4E as an emerging anticancer drug target.
Lu C; Makala L; Wu D; Cai Y
Expert Rev Mol Med; 2016 Jan; 18():e2. PubMed ID: 26775675
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of translation initiation as cancer therapeutics.
Lindqvist L; Pelletier J
Future Med Chem; 2009 Dec; 1(9):1709-22. PubMed ID: 21425987
[TBL] [Abstract][Full Text] [Related]
3. Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death.
Othumpangat S; Kashon M; Joseph P
Mol Cell Biochem; 2005 Nov; 279(1-2):123-31. PubMed ID: 16283521
[TBL] [Abstract][Full Text] [Related]
4. Signalling to eIF4E in cancer.
Siddiqui N; Sonenberg N
Biochem Soc Trans; 2015 Oct; 43(5):763-72. PubMed ID: 26517881
[TBL] [Abstract][Full Text] [Related]
5. Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy.
Wang G; Li Z; Li Z; Huang Y; Mao X; Xu C; Cui S
Biomed Pharmacother; 2017 Dec; 96():750-756. PubMed ID: 29049978
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
Pettersson F; Del Rincon SV; Miller WH
Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.
Graff JR; Konicek BW; Vincent TM; Lynch RL; Monteith D; Weir SN; Schwier P; Capen A; Goode RL; Dowless MS; Chen Y; Zhang H; Sissons S; Cox K; McNulty AM; Parsons SH; Wang T; Sams L; Geeganage S; Douglass LE; Neubauer BL; Dean NM; Blanchard K; Shou J; Stancato LF; Carter JH; Marcusson EG
J Clin Invest; 2007 Sep; 117(9):2638-48. PubMed ID: 17786246
[TBL] [Abstract][Full Text] [Related]
8. Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target.
Jia Y; Polunovsky V; Bitterman PB; Wagner CR
Med Res Rev; 2012 Jul; 32(4):786-814. PubMed ID: 22495651
[TBL] [Abstract][Full Text] [Related]
9. Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
Jacobson BA; Thumma SC; Jay-Dixon J; Patel MR; Dubear Kroening K; Kratzke MG; Etchison RG; Konicek BW; Graff JR; Kratzke RA
PLoS One; 2013; 8(11):e81669. PubMed ID: 24260583
[TBL] [Abstract][Full Text] [Related]
10. 5'-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma.
Srivastava RK; Khan J; Arumugam A; Muzaffar S; Guroji P; Gorbatyuk MS; Elmets CA; Slominski AT; Mukhtar MS; Athar M
J Invest Dermatol; 2021 Apr; 141(4):742-753.e10. PubMed ID: 32971126
[TBL] [Abstract][Full Text] [Related]
11. Targeting the oncogene eIF4E in cancer: From the bench to clinical trials.
Borden KL
Clin Invest Med; 2011 Dec; 34(6):E315. PubMed ID: 22129918
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.
Cao J; Sun X; Zhang X; Chen D
Clin Transl Oncol; 2018 Jun; 20(6):761-767. PubMed ID: 29086249
[TBL] [Abstract][Full Text] [Related]
13. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray.
Yang SX; Hewitt SM; Steinberg SM; Liewehr DJ; Swain SM
Oncol Rep; 2007 Feb; 17(2):281-7. PubMed ID: 17203162
[TBL] [Abstract][Full Text] [Related]
14. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer.
Topisirovic I; Siddiqui N; Orolicki S; Skrabanek LA; Tremblay M; Hoang T; Borden KL
Mol Cell Biol; 2009 Mar; 29(5):1152-62. PubMed ID: 19114552
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.
Thumma SC; Jacobson BA; Patel MR; Konicek BW; Franklin MJ; Jay-Dixon J; Sadiq A; De A; Graff JR; Kratzke RA
Cancer Gene Ther; 2015 Aug; 22(8):396-401. PubMed ID: 26227824
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities.
Topisirovic I; Ruiz-Gutierrez M; Borden KL
Cancer Res; 2004 Dec; 64(23):8639-42. PubMed ID: 15574771
[TBL] [Abstract][Full Text] [Related]
17. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Pettersson F; Yau C; Dobocan MC; Culjkovic-Kraljacic B; Retrouvey H; Puckett R; Flores LM; Krop IE; Rousseau C; Cocolakis E; Borden KL; Benz CC; Miller WH
Clin Cancer Res; 2011 May; 17(9):2874-84. PubMed ID: 21415224
[TBL] [Abstract][Full Text] [Related]
18. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
Xu M; Tao Z; Wang S; Jiang Y; Qu M
Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic translation initiation factor 4E is a cellular target for toxicity and death due to exposure to cadmium chloride.
Othumpangat S; Kashon M; Joseph P
J Biol Chem; 2005 Jul; 280(26):25162-9. PubMed ID: 15878868
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin.
Oridate N; Kim HJ; Xu X; Lotan R
Cancer Biol Ther; 2005 Mar; 4(3):318-23. PubMed ID: 15846092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
